Skip to content

Comparison of two venous access catheters for continuous haemofiltration in Intensive Care

In Intensive Care patients receiving haemofiltration is the Niagara or the Dolphin vasocath model more effective in terms of ease of insertion, infection rate, filter life and time to device failure?

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610001033033
Acronym
TARIF
Enrollment
60
Registered
2010-11-24
Start date
2011-02-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Continuous haemofiltration is performed in ICU to support patients with acute renal failure. The patient’s blood is pumped through a haemofilter where uraemic toxins are removed and then it is returned to the circulation. This is a continuous process that necessitates safe reliable large bore access to the circulation. The vascular access catheters are inserted percutaneously, usually into the femoral or internal jugular veins. There are number of commercial vascular access catheters available, but the industry standard for the past 10 years has been Bard Niagra, Bard Access Systems Inc. Utah, USA. This has large diameter channels, allowing high blood flows, but it occasionally can be difficult to insert. A new product, the Gambro Dolphin Protect, Gambro Lund Sweden, vascular access catheter has become available. It has a similar wide bore channels, but the shape of the cannula might make insertion easier and the catheter is impregnated with an antibacterial material that might reduce the rate of infection. These claimed advantages are only valuable if its basic function matches that of the industry standard. The aim of this study is to compare the two vascular access devices in a randomised controlled trial. The primary outcome measure will be trans-access resistance, a mathematically derived measure of the ease of blood flow through the catheter. Secondary outcome measures will be time to insert (in minutes) and ease of insertion measured on a visual analogue scale, presence of colonisation of the catheter at the time of removal (all tips will be sent for culture), presence of skin erythema at insertion site at time of removal, and haemofilter life (time to failure of haemofilters connected via the test cannula).

Interventions

Arm 1: Routine insertion of Dolphin protect vascular access device for haemofiltration Arm 2: Routine insertion of Niagara vascular access device for haemofiltration The Niagara device has large diameter channels, allowing high blood flows, but it occasionally can be difficult to insert as of its shape with a shoulder within the catheter. The Dolphin Gambro catheter has a wedge shape, which might make insertion easier and the catheter is impregnated with an antibacterial material that might red

Arm 1: Routine insertion of Dolphin protect vascular access device for haemofiltration Arm 2: Routine insertion of Niagara vascular access device for haemofiltration The Niagara device has large diameter channels, allowing high blood flows, but it occasionally can be difficult to insert as of its shape with a shoulder within the catheter. The Dolphin Gambro catheter has a wedge shape, which might make insertion easier and the catheter is impregnated with an antibacterial material that might reduce the rate of infection. Survival analysis will be used to examine duration of catheter placement and haemofilter life. Vascular access devices are retained for about seven days on average. Haemofilters generally last 12-36 hours. Therefore several haemofilters may be used for each vascular access device. Haemofiler life may be a surrogate measure of vascular access efficacy.

Sponsors

Kieran Hogan
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients requiring haemofiltration for acute renal failure

Exclusion criteria

Allergy to material of vascular device

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026